The L/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study was designed to investigate whether the LJN-type calcium channel blocker, cilnidipine, had a renoprotective effect compared with other calcium channel blockers. Twenty-five hypertensive patients with concomitant type 2 diabetes who had a urinary albumin-creatinine ratio (ACR) of 10-300 mg albuminJg creatinine and who had been treated with oral calcium channel blockers other than cilnidipine for more than 3 months were included. Patients' medication was changed to cilnidipine 10 mgJday or 20 mgJday without a washout period. Blood pressure and renal function were measured before and at 3 months after the new treatment. Heart rate was also determined as a marker for sympathetic nervous activity. After substitution of cilnidipine, blood pressure did not change significantly, but heart rate decreased significantly from 73.9 ±7.1 beatsJmin to 72.0 ± 8.4 beatsJmin, and the log-transformed urinary ACR decreased to 82.9 ± 49.4% of baseline values. The changes in urinary ACR and heart rate showed a significant positive correlation. Thus, there was a strong indication that cilnidipine may exert its renoprotective effect by inhibiting sympathetic nervous activity.

Original languageEnglish
Pages (from-to)602-610
Number of pages9
JournalJournal of International Medical Research
Volume38
Issue number2
DOIs
Publication statusPublished - 2010 Jan 1
Externally publishedYes

Fingerprint

N-Type Calcium Channels
L-Type Calcium Channels
Albuminuria
Calcium Channel Blockers
Heart Rate
Creatinine
Albumins
Blood pressure
Blood Pressure
Medical problems
Type 2 Diabetes Mellitus
Substitution reactions
cilnidipine
Kidney

Keywords

  • Diabetic nephropathy
  • L/N-type calcium channel blocker
  • Sympathetic nervous activity
  • Urinary albumin

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

@article{f3eaf146ce194156a2dc4b079c328b6e,
title = "The L/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2",
abstract = "This study was designed to investigate whether the LJN-type calcium channel blocker, cilnidipine, had a renoprotective effect compared with other calcium channel blockers. Twenty-five hypertensive patients with concomitant type 2 diabetes who had a urinary albumin-creatinine ratio (ACR) of 10-300 mg albuminJg creatinine and who had been treated with oral calcium channel blockers other than cilnidipine for more than 3 months were included. Patients' medication was changed to cilnidipine 10 mgJday or 20 mgJday without a washout period. Blood pressure and renal function were measured before and at 3 months after the new treatment. Heart rate was also determined as a marker for sympathetic nervous activity. After substitution of cilnidipine, blood pressure did not change significantly, but heart rate decreased significantly from 73.9 ±7.1 beatsJmin to 72.0 ± 8.4 beatsJmin, and the log-transformed urinary ACR decreased to 82.9 ± 49.4{\%} of baseline values. The changes in urinary ACR and heart rate showed a significant positive correlation. Thus, there was a strong indication that cilnidipine may exert its renoprotective effect by inhibiting sympathetic nervous activity.",
keywords = "Diabetic nephropathy, L/N-type calcium channel blocker, Sympathetic nervous activity, Urinary albumin",
author = "M. Tanaka",
year = "2010",
month = "1",
day = "1",
doi = "10.1177/147323001003800222",
language = "English",
volume = "38",
pages = "602--610",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "2",

}

TY - JOUR

T1 - The L/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2

AU - Tanaka, M.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - This study was designed to investigate whether the LJN-type calcium channel blocker, cilnidipine, had a renoprotective effect compared with other calcium channel blockers. Twenty-five hypertensive patients with concomitant type 2 diabetes who had a urinary albumin-creatinine ratio (ACR) of 10-300 mg albuminJg creatinine and who had been treated with oral calcium channel blockers other than cilnidipine for more than 3 months were included. Patients' medication was changed to cilnidipine 10 mgJday or 20 mgJday without a washout period. Blood pressure and renal function were measured before and at 3 months after the new treatment. Heart rate was also determined as a marker for sympathetic nervous activity. After substitution of cilnidipine, blood pressure did not change significantly, but heart rate decreased significantly from 73.9 ±7.1 beatsJmin to 72.0 ± 8.4 beatsJmin, and the log-transformed urinary ACR decreased to 82.9 ± 49.4% of baseline values. The changes in urinary ACR and heart rate showed a significant positive correlation. Thus, there was a strong indication that cilnidipine may exert its renoprotective effect by inhibiting sympathetic nervous activity.

AB - This study was designed to investigate whether the LJN-type calcium channel blocker, cilnidipine, had a renoprotective effect compared with other calcium channel blockers. Twenty-five hypertensive patients with concomitant type 2 diabetes who had a urinary albumin-creatinine ratio (ACR) of 10-300 mg albuminJg creatinine and who had been treated with oral calcium channel blockers other than cilnidipine for more than 3 months were included. Patients' medication was changed to cilnidipine 10 mgJday or 20 mgJday without a washout period. Blood pressure and renal function were measured before and at 3 months after the new treatment. Heart rate was also determined as a marker for sympathetic nervous activity. After substitution of cilnidipine, blood pressure did not change significantly, but heart rate decreased significantly from 73.9 ±7.1 beatsJmin to 72.0 ± 8.4 beatsJmin, and the log-transformed urinary ACR decreased to 82.9 ± 49.4% of baseline values. The changes in urinary ACR and heart rate showed a significant positive correlation. Thus, there was a strong indication that cilnidipine may exert its renoprotective effect by inhibiting sympathetic nervous activity.

KW - Diabetic nephropathy

KW - L/N-type calcium channel blocker

KW - Sympathetic nervous activity

KW - Urinary albumin

UR - http://www.scopus.com/inward/record.url?scp=77953709427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953709427&partnerID=8YFLogxK

U2 - 10.1177/147323001003800222

DO - 10.1177/147323001003800222

M3 - Article

C2 - 20515573

AN - SCOPUS:77953709427

VL - 38

SP - 602

EP - 610

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 2

ER -